DTx WEST 2020
3RD ANNUAL

DTx WEST 2020

February 18-20 | San Mateo, CA

Translating Value into Commercial Reality

Registration Agenda

2020 Partners

Knowledge Partners
Bright Insight

BrightInsight, a Flex Company, provides the leading global regulated digital health platform for biopharma and medtech. Our medical-grade Internet of Things (IoT) platform is built under a Quality Management System to support and optimize regulated drugs, devices and software through integrated data and actionable insights to enable customers to drive increased patient adherence and engagement.

The BrightInsight™ Platform uses software and services to capture, transmit and analyze data from CE-marked and FDA-regulated medical devices, combination products, apps and Software as a Medical Device, in compliance with security, privacy and regulatory requirements.

IQVIA

IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on helping healthcare clients find better solutions for patients. Formed through the merger of IMS Health and Quintiles, IQVIA applies Human Data Science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes.

Noom

Noom is the world’s leading behavior change company, disrupting the weight loss and healthcare industries. By combining the power of artificial intelligence, mobile tech, and psychology with the empathy of over 1,000 personal coaches, Noom helps people live healthier lives by changing their habits for the long-term. More than 50 million people have benefited from Noom’s behavior change courses.

The company is headquartered in New York City with offices in Seoul and Tokyo.

Learn More

Supporters
Click Therapeutics

Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes.

Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.

Learn More.

JAZZ Venture Partners

JAZZ Venture Partners invests in companies that extend the boundaries of human performance — improving how we live, learn, work, play, and experience the world.

We seek breakthroughs at the intersection of digital technology and neuroscience that are influencing the human experience, such as augmented reality, artificial intelligence, immersive gaming, and closed-loop human-computer systems.

Our portfolio companies are unlocking human potential in health, mind-body wellness, accelerated learning and training, sports, entertainment, and the enterprise.

Learn More.

Otsuka
Sanofi

Sanofi Digital Medicine, under the Chief Medical Office, improves patient outcomes through the development of innovative technology-driven solutions that when combined with drugs, improve treatment efficacy, safety, adherence and overall experience.

Learn More.

Key Numbers of DTx
300+
Attendees

Be part of the 300+ person audience of senior executives who are driving forward the development of Digital Therapeutics

40+
Expert speakers

Learn from the industry-defining speaker faculty, comprised of the pioneers of the industry and the most exciting new-comers

7th
in the series

Established in 2017, the DTx series is the home for the Digital Therapeutics community

The DTx Series is my go-to place for staying up-to-date and meeting all of the key players in this promising new digital health category.

Bozidar Jovecevic, VP, Global Head of Digital Therapeutics, Sanofi

I am excited to attend DTx for the fourth time. Whether as a presenter or part of the audience, I learn so much from other Digital Therapeutic executives and attendees about topics ranging from clinical trials to commercialization and everything in between.

Debra Reisenthel, Founding CEO, Palo Alto Health Sciences

I have been to the two editions of DTx West and I’m looking forward to attending DTx East this year. The conference brings together key leaders from across the digital health space to discuss new ideas and ongoing trends that are useful takeaways to bring back to my team.

Pablo Pantaleoni, VP & General Manager, Headspace Health

“Thanks for catalyzing the industry forward in this emerging field. Looking forward to the next one”

Cris de Luca - Global Director, Innovation, Johnson and Johnson Technology

“The DTx Series is a fantastic set of meetings. The quality of the investors, entrepreneurs and companies never fails to impress me, and I always leave having learned a lot”

John Spinale - General Partner, JAZZ Venture Partners

“DTx is an inclusive event, where the participants truly believe that the rising tide will raise all boats”

Mette Dyhrberg - Founder and CEO, MyMee Inc

“DTx is a great event! there is a great mix of digital innovators and large companies which deliver high-quality content. I learn a lot and it’s great to see this community come together and have authentic interactions”

Adam Kaufman - CEO, Canary Health

Speaker Faculty

ANAND IYER
ANAND IYER
Chief Strategy Officer
WellDoc
ANAND IYER
Chief Strategy Officer
WellDoc

Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University.

JENNIFER LAGUARDIA
JENNIFER LAGUARDIA
Senior Director of Behaviour Science
Omada Health
JENNIFER LAGUARDIA
Senior Director of Behaviour Science
Omada Health
VEENA RAO
VEENA RAO
Senior Director, Search & Evaluation, Device Delivery, Connected Systems, & Digital Health
Eli Lilly
VEENA RAO
Senior Director, Search & Evaluation, Device Delivery, Connected Systems, & Digital Health
Eli Lilly
MARK BINI
MARK BINI
VP, New Solutions
Express Scripts
MARK BINI
VP, New Solutions
Express Scripts

Mark Bini is the Vice President of Innovation and Member Experience at Express Scripts. Since 2008, Mark has been a key contributor to the advancement of Express Scripts’ solution portfolio. Over this time, he has worked with other thought leaders to design and employ an industry-leading, behavior-centric approach to innovation that places clients and members in the “front seat” of product development. Mark is also responsible for Express Scripts’ suite of digital therapeutic solutions that includes remote monitoring solutions for diabetes, asthma, and medication non-adherence. Mark’s approach to innovation and the solutions that have spawned from it have played a key role in Express Scripts being named to Forbes’ World’s Most Innovative Companies.

JONAS DUSS
JONAS DUSS
Co-Founder, US CEO
Kaia Health
JONAS DUSS
Co-Founder, US CEO
Kaia Health
JENNA CARL
JENNA CARL
VP of Clinical Development & Medical Affairs
Big Health
JENNA CARL
VP of Clinical Development & Medical Affairs
Big Health
SEAN DUFFY
SEAN DUFFY
Co-Founder & CEO
Omada Health
SEAN DUFFY
Co-Founder & CEO
Omada Health
EVERETT CROSLAND
EVERETT CROSLAND
SVP, Commercial
AppliedVR
EVERETT CROSLAND
SVP, Commercial
AppliedVR
DEREK RICHARDS
DEREK RICHARDS
Chief Science Officer
SilverCloud Health
DEREK RICHARDS
Chief Science Officer
SilverCloud Health
MEGAN OSER
MEGAN OSER
Vice President of Clinical Innovation
Mahana Therapeutics
MEGAN OSER
Vice President of Clinical Innovation
Mahana Therapeutics
ANIL JINA
ANIL JINA
Chief Medical Officer
Akili Interactive
ANIL JINA
Chief Medical Officer
Akili Interactive

Anil is a physician executive based in the Boston area and has over 20 years of global healthcare and biopharmaceutical experience. He studied medicine in Ireland and worked clinically in the Irish healthcare system before moving to the biopharmaceutical industry where he has held roles of increasing responsibility across different companies, different therapeutic areas and different geographies.

Anil’s interest in developing world healthcare started while he was studying medicine at the Royal College of Surgeons in Ireland, where he raised money to purchase medical supplies for a rural health clinic in Tanzania, East Africa, and delivered them personally as well as working in the clinic for 3 months. More recently he has been instrumental in establishing a charitable access program to rare disease medicines which is now operating across 10 countries.

TRINA HISTON
TRINA HISTON
Senior Principal Consultant, Prevention, Wellness & Digital Health
Kaiser Permenente
TRINA HISTON
Senior Principal Consultant, Prevention, Wellness & Digital Health
Kaiser Permenente

Trina has built an extensive career in addressing prevention, wellbeing, behavior change, and emotional health by translating evidence into practice in healthcare in Ireland and the USA. Trina has been working in the digital space since 2010.

 

Trina is a Senior Principal Consultant in Prevention, Wellness, and Digital Health at Kaiser Permanente’s Care Management Institute. Trina obtained a Ph.D. in health psychology from University College Cork, Ireland. Trina has published on the topic of Obesity and has spoken at numerous conferences. Trina has consulted on games for health, including Kaiser Permanente’s “Amazing Food Detective” and on tech solutions for weight management (Picture it!) in collaboration with Ayogo. Trina is currently co-lead for Project Chamai (Greek for “grounded”) to deploy an ecosystem of digital mental health tools in Kaiser Permanente to support emotional wellness.

 

Trina has been invited to act as an expert advisor and to educate numerous organizations, including the Centers for Disease Control, CMS, National Committee for Quality Assurance (NCQA), National Quality Forum (NQF), Prescription for Physical Activity Task Force, and the Obesity Society and Ayogo. Trina is a member of the Society for Behavioral Medicine (SBM), the American Psychological Association (APA), The Obesity Society (TOS), and Digital Medicine Society (DiME).

 

Trina enjoys bringing the evidence to life for front line teams and implementing technology solutions to support people on their journey toward health.

ANDY MOLNAR
ANDY MOLNAR
Senior Director, Market Access
Cognoa
ANDY MOLNAR
Senior Director, Market Access
Cognoa
PABLO PANTALEONI
PABLO PANTALEONI
VP and General Manager
Headspace
PABLO PANTALEONI
VP and General Manager
Headspace
KAL PATEL
KAL PATEL
CEO & Co-Founder
Bright Insight, a Flex Company
KAL PATEL
CEO & Co-Founder
Bright Insight, a Flex Company

Kal Patel has over 20 years of experience in pharma, medtech and regulated digital health. Prior to joining BrightInsight, he was Chief Commercial Officer for Doctor on Demand, now the nation’s largest video-medicine provider, with backing from Andreessen Horowitz, Venrock, Google Ventures, and Qualcomm.

Kal founded and built Amgen’s Digital Health business unit where he had end-to-end responsibility for developing and commercializing a portfolio of digital products in connected devices, advanced algorithms/decision making and next-generation marketing, where he launched multiple regulated devices. Kal also serves as a Senior Advisor in Digital Health to the Boston Consulting Group and various digital health startups

SAEJU JEONG
SAEJU JEONG
Co-Founder & CEO
Noom
SAEJU JEONG
Co-Founder & CEO
Noom

Saeju Jeong, CEO and co-founder of Noom, is a serial entrepreneur and tech company angel investor. Noom is the world’s largest behavior change company, disrupting the weight loss and healthcare industries. By combining the power of artificial intelligence, mobile tech, and psychology with the empathy of thousands of personal coaches, Noom helps people live healthier lives by changing their long-term habits. More than 50 million people have benefited from Noom’s behavior change courses, and Noom’s platform is already being used by leading healthcare and pharmaceutical companies like Novo Nordisk to improve treatment outcomes for patients worldwide. 

Noom, Inc. is backed by Sequoia Capital, RRE, Samsung and Qualcomm.

CLARE PURVIS
CLARE PURVIS
Director, Behaviour Sciences
Headspace
CLARE PURVIS
Director, Behaviour Sciences
Headspace
BRYCE WILLIAMS
BRYCE WILLIAMS
VP, Lifestyle Medicine
Blue Shield of California
BRYCE WILLIAMS
VP, Lifestyle Medicine
Blue Shield of California
KARA TIBBE
KARA TIBBE
Training and Development Specialist
Spectrum Health
KARA TIBBE
Training and Development Specialist
Spectrum Health

Kara Tibbe leads health system wide care transformation initiatives centered around digital health innovation. At Spectrum Health, she leads projects focused on virtual and mobile health integration within primary and specialty care. Spectrum Health is the first health system in the US to integrate IQVIA’s App prescription platform “AppScript” into the EMR which enables mobile app prescriptions to be embedded into clinician workflow, a project that Kara leads.  Kara’s role encompasses vetting digital therapeutics for employer and health care settings and operationalizing into seamless patient care.

Her background is in Business Administration and Science.

EDDIE MARTUCCI
EDDIE MARTUCCI
CEO
Akili Interactive Labs
EDDIE MARTUCCI
CEO
Akili Interactive Labs

Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City, MO, focused on healthcare entrepreneurship. Prior to that, he completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on structure-based drug design, where he led a research project that identified two novel chemical scaffolds as proof-of-concept compounds for novel therapy. Eddie received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University.

ALEX WALDRON
ALEX WALDRON
Chief Strategy Officer
Pear Therapeutics
ALEX WALDRON
Chief Strategy Officer
Pear Therapeutics

Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations. He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals. Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.

ELLI KAPLAN
ELLI KAPLAN
Co-Founder & CEO
Neurotrack
ELLI KAPLAN
Co-Founder & CEO
Neurotrack

Elli Kaplan is the co-founder and CEO of Neurotrack. Her career spans two decades in the public and private sectors, including at the White House, the State and Treasury Departments, and the United Nations Development Program. Elli has also held positions with AIG, Goldman Sachs and multiple startups. She has won SXSW’s best new startup and DEMO God awards, the J&J World Without Disease Challenge, and presented at TEDx, TechCrunch Disrupt, the Royal Society of Medicine, Wired and the New York Times. Elli has an M.B.A. from Harvard Business School.

ALEX PETROV
ALEX PETROV
Founder & CEO
Yes Health
ALEX PETROV
Founder & CEO
Yes Health
CHRIS WASDEN
CHRIS WASDEN
Head of HappifyDTx
Happify Health
CHRIS WASDEN
Head of HappifyDTx
Happify Health
DAVID STEVENSON
DAVID STEVENSON
Managing Director
Merck Global Health Innovation Fund
DAVID STEVENSON
Managing Director
Merck Global Health Innovation Fund
EDWARD COX
EDWARD COX
CEO
Dthera Sciences
EDWARD COX
CEO
Dthera Sciences

Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.

REBECCA LYONS
REBECCA LYONS
Program Manager, Principal, Enhanced Clinical Programs
Blue Shield of California
REBECCA LYONS
Program Manager, Principal, Enhanced Clinical Programs
Blue Shield of California

Rebecca Lyons is a program manager on Blue Shield of California’s Enhanced Clinical Program & HealthCare value solutions team . Prior to a brief time away to work on patient engagement at a biotech startup, she coordinated the partnerships with medical groups and hospitals while a program manager on BSC’s Accountable Care Organization team. Prior to BSC, she held various positions in health care delivery such as performance improvement, program management and clinical research coordinating at various institutions such as Cedars-Sinai Health System, Rady Children’s Hospital, San Diego and Columbia-NY Presbyterian Hospital. She holds an undergraduate degree in Developmental Psychology from UC San Diego and an MPH from Columbia University.

BRENT VAUGHAN
BRENT VAUGHAN
CEO & Co-Founder
Cognoa
BRENT VAUGHAN
CEO & Co-Founder
Cognoa

Brent is the CEO and co-founder of Cognoa, an AI-based digital precision medicine behavioral health platform. Cognoais developing innovative digital diagnostics and digital therapeutics to change the standard of care for pediatric behavioral health and improve outcomes by enabling earlier diagnosis, treatment, and increased engagement. Brent has over 20 years industry experience working with diagnostics, therapeutics and digital consumer health. Prior to Cognoa, Brent was the co-founder and COO of WellnessFX, an award-winning digital health company that increased patient engagement by providing direct-to-consumer diagnostics and integrated telemedicine. Before working in digital health, Brent worked in product and commercial roles in Novartis, Nektar, Roche and Lily.

VAS BAILEY
VAS BAILEY
Partner
Artis Ventures
VAS BAILEY
Partner
Artis Ventures
SIVA NADARAJAH
SIVA NADARAJAH
Co-Founder & President
JOGO Health
SIVA NADARAJAH
Co-Founder & President
JOGO Health
MIKAEL ELIASSON
MIKAEL ELIASSON
Global Head of Innovation, Neuroscience Product Development
Genentech
MIKAEL ELIASSON
Global Head of Innovation, Neuroscience Product Development
Genentech
KEVIN APPELBAUM
KEVIN APPELBAUM
Co-Founder & CEO
Better Therapeutics
KEVIN APPELBAUM
Co-Founder & CEO
Better Therapeutics
JO MASTERSON
JO MASTERSON
Chief Product Officer & COO
2morrow Inc
JO MASTERSON
Chief Product Officer & COO
2morrow Inc

Jo is fascinated by the convergence of mobile technology and behavioral science, especially surrounding the area of healthcare. At 2Morrow, Jo leads the research and program development efforts to make evidence-based behavior modifications programs more accessible by putting them directly in the hands of those who need them via their smartphones. Focused on drivers that affect chronic disease (i.e. smoking, weight, stress, chronic pain management), 2Morrow’s evidence-based platform makes it easier and more convenient to include behavioral science into existing health care treatment plans. 2Morrow distributes programs distributed via employers, wellness platforms, health plans, providers and public health. Jo is a past “40 under 40“ who started her career as a nurse and has worked in healthcare, education and technologies companies.

KENICHIRO NISHII
KENICHIRO NISHII
Lead, Regulatory Affairs and Business Development
CureApp
KENICHIRO NISHII
Lead, Regulatory Affairs and Business Development
CureApp

Ken is a regulatory affairs and business development lead at CureApp North America. He is specialized in US regulatory compliance with a strong engineering background. Before joining CureApp, he worked for regulatory compliance and business consulting company where he completed more than 14 regulatory submissions ranging from De Novo and 510(k) to Q-subs (Pre-sub, submission issue, supplemental) and variance requests.

With a variety of regulatory submission experience for products from early to late stages of development, he is currently responsible for CureApp’s US regulatory compliance, acting as a vital liaison between Japanese and US regulatory agencies.

In Japan, CureApp recently completed a phase III clinical trial and regulatory submission to the Japanese PMDA for a smoking cessation app. CureApp would like to share insights from outside of the US regulatory environment at the DTx East meeting.

LIZ ROCKETT
LIZ ROCKETT
Director
Kaiser Permanente Ventures
LIZ ROCKETT
Director
Kaiser Permanente Ventures
HAKIM YADI
HAKIM YADI
Co-Founder & CEO
Closed Loop Medicine
HAKIM YADI
Co-Founder & CEO
Closed Loop Medicine
CHRIS HOGG
CHRIS HOGG
Chief Commercial Officer
Propeller Health
CHRIS HOGG
Chief Commercial Officer
Propeller Health
ACACIA PARKS
ACACIA PARKS
Chief Scientist
Happify
ACACIA PARKS
Chief Scientist
Happify

Dr. Parks’ research focuses on self-help methods for increasing well-being via books and digital technology. She is Chief Scientist for tech startup Happify, which brings the cutting edge in research-based well-being interventions to large businesses, health plans, and consumers. Her research spans across the whole spectrum of wellness, from non-distressed consumers to stressed employees, sufferers of chronic health conditions, and individuals with depression and/or anxiety. She works to pioneer new methodology in the study of digital therapeutics, especially when it comes to outcomes assessment. Her work has been published in peer-reviewed journals, and in addition to editing three books, she is also an Associate Editor at the Journal of Positive Psychology.

SHARIEF TARAMAN
SHARIEF TARAMAN
Chief Medical Officer
Cognoa
SHARIEF TARAMAN
Chief Medical Officer
Cognoa

Sharief Taraman, M.D. is the Chief Medical Officer at Cognoa, Inc., a Silicon Valley based startup that develops artificial intelligence-based digital diagnostics and personalized therapeutics that provide accurate, earlier diagnoses and more effective treatments to improve outcomes and lower behavioral healthcare costs. He is a Magna Cum Laude graduate of the University of Michigan having majored in Biochemistry. He completed his medical education at Wayne State University School of Medicine in 2006 and went on to complete residency training in Pediatrics and Pediatric Neurology at the Children’s Hospital of Michigan. Dr. Taraman is dual board certified in Neurology with special qualifications in child neurology from the American Board of Psychiatry and Neurology and in Clinical Informatics from the American Board of Preventative Medicine. He remains clinically active as the Division Chief of the CHOC Children’s Specialists Pediatric Neurology Division and a Health Sciences Associate Clinical Professor at UC Irvine School of Medicine. Dr. Taraman is active in the community as a board member of the AAP Orange County Chapter, Irvine Unified School District Medical Advisory Board, and volunteering for Girl Scouts of Orange County and the Capistrano Unified School District.

PETER HAMES
PETER HAMES
Co-Founder & Chief Executive Officer
Big Health
PETER HAMES
Co-Founder & Chief Executive Officer
Big Health
Peter Hames is co-founder and CEO of Big Health, a company creating “digital medicine” – fully automated, software-based CBT that is as scalable as drugs yet as effective as in person therapy. Peter is an NHS Innovation Fellow, and holds a Masters in Experimental Psychology from Oxford University.
 
It was his own experience of insomnia, and how he overcame it, that inspired him to found Big Health and create Sleepio, a digital sleep improvement program that is currently available to over 12 million people through partnerships with US employers and the UK’s National Health Service (NHS).
DEBRA REISENTHEL
DEBRA REISENTHEL
Founding CEO
Palo Alto Health Sciences
DEBRA REISENTHEL
Founding CEO
Palo Alto Health Sciences

Debra is founding CEO of Palo Alto Health Sciences, a digital therapeutic company providing evidence-based, at-home, drug-free solutions in behavioral health. Freespira® is an FDA-cleared treatment for panic disorder, panic attacks and PTSD. Debra has broad operational and leadership experience in start- ups, corporate and nonprofit organizations. Prior to PAHS, Debra worked with a Bay Area incubator to develop a women’s health product, was founding CEO of Novasys Medical, and was VP/GM of a Division of Tyco, inc. (Mallinckrodt, Nellcor). Debra holds a B.A., MBA and R.R.T credentials. She has been a guest entrepreneur for 5 years as part of an HBS case study. Given her deep knowledge of digital therapeutics and medical devices, she is now an Advisor to DTxCC and a Consultant in this growing market.

ADAM KAUFMAN
ADAM KAUFMAN
President & Chief Executive Officer
Canary Health
ADAM KAUFMAN
President & Chief Executive Officer
Canary Health

Adam Kaufman is a health pioneer, having led the building of digital behavior change programs used by dozens of healthcare organizations and tens of thousands of consumers. A health economist, engineer and company executive, Adam speaks to audiences nationwide on the accelerating trend of chronic illness, its impact on lives and costs of care and proven approaches to arresting disease trajectories.
Recognized as a leader in patient engagement and population health, Canary Health works with health plans such as Kaiser Permanente, Humana, GEHA and Blue Shield of California to empower members to better health self-management.

JEFFREY ABRAHAM
JEFFREY ABRAHAM
Vice President
Market Access & Trade, Akili Interactive
JEFFREY ABRAHAM
Vice President
Market Access & Trade, Akili Interactive

Jeffrey has over 10 years’ experience in healthcare services/operations, market access, reimbursement, and HEOR. Jeffrey has worked both on the industry and consulting side of pharmaceuticals, medical devices, and diagnostics. His previous experience includes global work in the US, EU, and select APAC markets, covering 30 different products. Most recently he served as the Value Development Lead for The Medicines Company and their surgery/perioperative products. He was responsible for a value and evidence based approach to access and commercialization. He graduated from Boston University with a Bachelor of Health Sciences, Master of Science in Physical Therapy, and a Master of Business Administration.

MEGAN CODER
MEGAN CODER
Executive Director
Digital Therapeutics Alliance
MEGAN CODER
Executive Director
Digital Therapeutics Alliance

Megan Coder, PharmD, MBA, is Executive Director of the Digital Therapeutics Alliance. DTA’s mission is to broaden the understanding, adoption, and integration of clinically-validated digital therapeutic solutions into mainstream healthcare through education, advocacy, and research.

With more than a decade of experience in the healthcare industry, Megan’s expertise extends from strategic growth and partnership development within the digital health sector, to the direct delivery of patient care. Prior to joining DTA, Megan worked with Voluntis, Iodine, the Pharmaceutical Care Management Association, and the Pharmacy Technician Certification Board.

A proud Badger, Megan graduated from the University of Wisconsin—Madison School of Pharmacy and completed an Executive Residency in Association Management & Leadership with the American Pharmacists Association.

ANTOUN NABHAN
ANTOUN NABHAN
Vice President, Corporate Development
Pear Therapeutics
ANTOUN NABHAN
Vice President, Corporate Development
Pear Therapeutics
RICARDO DOS SANTOS
RICARDO DOS SANTOS
Entrepreneur in Residence
ResMed
RICARDO DOS SANTOS
Entrepreneur in Residence
ResMed
PIERRE LEURENT
PIERRE LEURENT
Chief Executive Officer
Voluntis
PIERRE LEURENT
Chief Executive Officer
Voluntis

Pierre Leurent, CEO and founder of VOLUNTIS, has more than 19 years of international experience in digital health in the United States and Europe. Voluntis’ mission is to improve the real-world value of therapies by providing patients and clinicians with therapeutic companion software. Its clinical-grade, regulatory-cleared mobile and cloud solutions embed advanced real-time decision support algorithms to enable patients to better manage their treatment in remote collaboration with their healthcare team. Prior to starting Voluntis in 2001, Pierre worked at GE Medical Systems, where he took part in the development of medical imaging software. He also occupied several positions at HealthCenter Internet Services, a San Francisco-based vendor of electronic medical record solutions.

Thursday, 20th February Summit Workshops
  • Workshop 1: The Business of Digital Therapeutics
  • Workshop 2: Separating the Digital from the Traditional
Workshop 1: The Business of Digital Therapeutics
The Business of Digital Therapeutics - WORKSHOP LEADERS

Debra Reisenthel, Founding CEO, Palo Alto Health Sciences
Everett Crosland, SVP of Market Access, Reimbursement & Government Affairs, AppliedVR
Jonas Duss, US Chief Executive Officer, Kaia Health
Antoun Nabhan, VP, Corporate Development, Pear Therapeutics

9:00am
Presentation: An Inside Look at the Business of Digital Therapeutics
  • A brief overview of the various business models adopted by digital therapeutic companies
  • An insight into the various routes to market
  • Can DTx companies exist with both FDA and Non-FDA regulated therapeutics or do you have to “pick a side”
9:30am
Breakout Discussions

Splitting into smaller groups, you will discuss the intricacies of the business of digital therapeutics and hear views on how best to successfully run a business in the DTx industry.

  • What are the current business models being used within the industry and which are demonstrating the most success?
  • How do some business models favor certain types of digital therapeutic over others?
  • Can a digital therapeutic company successfully develop and market both FDA & non-FDA regulated digital therapeutics?
  • What are the route to market opportunities available to the DTx industry?
10:30am
Refreshment Break
11:00am
Feedback Discussions

Representative(s) from each group share the main points from their discussion to the whole group. Additional questions from moderators and other group members will be raised during this collaborative discussion. 

Summary thoughts will then be shared by the moderator(s) and all participants will leave with the below:

 

Leave this workshop with:
  • A deeper understanding of the various business models demonstrated by digital therapeutic companies
  • Up-to-date information on business models of varying successes in the current industry
  • A clear understanding of if it’s possible to successfully a dual entity business or if companies truly have to “pick a side”
  • A clear understanding of current routes to market and their intricacies
  • Your questions answered by industry leaders and your peers
12:00pm
End of workshop
Download Agenda
Workshop 2: Separating the Digital from the Traditional
Separating the Digital from the Traditional - WORKSHOP LEADERS

Acacia Parks, Chief Scientist, Happify
Jenna Carl, VP of Clinical Development & Medical Affairs, Big Health
Derek Richards, Chief Science Officer, SilverCloud Health
Anil Jina, Chief Medical Officer, Akili Interactive

1:00pm
Presentation: An Introduction into Digital Therapeutic Clinical Trials
  • How do digital therapeutic clinical trials differ from traditional drug trials?
  • An introduction of comparison groups and digital trial design
1:20pm
Panel Discussion: A Deep-Dive into Research Design Considerations

Led by leaders in the industry all with in-depth experience of DTx clinical trials, this panel will dive into clinical trial considerations when designing trials for digital therapeutics

  • What are the requirements when designing digital therapeutic clinical trials?
  • What does the FDA require from clinical trials for them to be acceptable?
  • What does a SHAM/placebo look like in the DTx clinical trial?
  • Should DTx companies and the FDA be working together to produce the right SHAM for each trial?
2:10pm
Freewrite

This is your chance to finalize your notes and prepare questions for the workshop leaders and your peers for after the break!

2:15pm
Refreshment Break
2:45pm
Breakout Discussions

Splitting into smaller groups, each group will discuss their own views on digital therapeutic clinical trials and work on how best to move forward in this space.

  • What are the current issues we face when designing clinical trials for digital therapeutics?
  • What considerations should you have in mind when designing SHAM trials?
  • What are the current guidelines for DTx clinical trials outlined by the FDA?
  • How can we work with governing bodies to ensure DTx clinical trials are both suitable and feasible?
  • What does a suitable and usable SHAM trial look like?
3:20pm
Feedback Discussions

Representatives from each group will share their main points from their discussion with the whole workshop.

Workshop leaders and members from all groups will facilitate the discussion with their own thoughts and questions in this collaborative session.

Summary thoughts will be shared by workshop leaders and all participators will leave with the below:

 

Leave this workshop with:
  • A clear understanding of the clinical trial landscape for digital therapeutics
  • A deeper understanding of how best to build a SHAM/placebo for a DTx clinical trial
  • An understanding of current FDA clinical trial guidelines in the space
  • A greater understanding of important considerations to keep in mind when designing a DTx clinical trial
  • Your questions answered by industry-leading experts and your peers
4:00pm
End of Workshop
Download Agenda

Summit Agenda

  • Day 1: Tuesday, 18th February
  • Day 2: Wednesday, 19th February
Day 1: Tuesday, 18th February
8:00
Day One - Registration, Breakfast & Networking
9:00
Chair’s Opening Remarks & Setting the Scene

Adam Kaufman, President & CEO, Canary Health

9:10
Fireside Chat: How can Healthplan Partnerships be an Accelerant to DTx Innovation, Commercialisation and Patient Adoption?

Bryce Williams, VP, Lifestyle Medicine, Blue Shield of California
Alex Petrov, Founder & CEO, Yes Health
Kevin Appelbaum, Co-Founder & CEO, Better Therapeutics

9:50am
Presentation: Noom, Healthier Lives Through Behavior Change

Saeju Jeong, Co-Founder & CEO, Noom

10:15am
Panel Discussion: How can we Achieve Replicable Digital Therapeutics Reimbursement?

Moderated by Brent Vaughan,  Chief Executive Officer, Cognoa
Sean Duffy, Co-Founder & CEO, Omada Health
Rebecca Lyons, Program Manager, Principal, Enhanced Clinical Programs,Blue Shield of California
Alex Waldron, Chief Strategy Officer, Pear Therapeutics
Peter Hames, Co-Founder & CEO, Big Health

11:00am
Morning Refreshments and Networking
Day 1 will now Split into 2 Tracks

Attendees are welcome to jump between tracks as they choose

Track 1

Defining Evidence Standards for Digital Therapeutics

Chair: Acacia Parks, Chief Scientist, Happify

11:40am
Presentation: Is there a Bar of Validation for Digital Therapeutics

Acacia Parks, Chief Scientist, Happify

12:05pm
Panel Discussion: How does Lack of Clarity in Setting the Bar for Evidence effect Value?

Veena Rao, Senior Director, Search & Evaluation, Device Delivery, Connected Systems & Digital Health, Eli Lilly
Mark Bini, VP, New Solutions, Express Scripts
Jo Masterson, Co-Founder. CPO & COO, 2morrow Inc.
Brian Clancy, Co-Lead & Associate Director, AppScript, IQVIA

Track 2

Building the Value Proposition for Digital Therapeutics

Chair: Adam Kaufman, President & CEO, Canary Health

11:40am
Presentation: Understanding the Commercial Landscape of Digital Therapeutics

Antoun Nabhan, VP, Corporate Development, Pear Therapeutics

12:05pm
Panel Discussion: Building the Bridge between Evidence and Value

Jeff Abraham, VP of Market Access & Trade, Akili Interactive
Jennifer LaGuardia, Senior Director of Behaviour Science, Omada Health
Andy Molnar, Senior Director, Market Access, Cognoa
Clare Purvis, Director, Behaviour Sciences, Headspace

12:45pm
Lunch & Networking
Method of Evidence Generation and Translation
1:55pm
Presentation: The In's and Out's of Randomized Controlled trials for DTx Clinical Validation

Derek Richards, Chief Science Officer, Silvercloud Health

2:20pm
Panel Discussion: Understanding the Fundamentals of Demonstrating Clinical Efficacy

Moderated by Sharief Taraman, Chief Medical Office, Cognoa
Debra Reisenthel, Founding CEO Palo Alto Health Sciences
Jenna Carl, VP of Clinical Development & Medical Affairs, Big Health
Jonas Duss, US Chief Executive Officer, Kaia Health
Megan Oser, VP of Clinical Innovation, Mahana Therapeutics

Translating the Value Proposition of Digital Therapeutics
1:55pm
Presentation: Pharma Partnerships in Action

Chris Wasden, Head of HappifyDTx, Happify Health

2:20pm
Presentation: Implementing Digital Therapeutics into the Core Efforts alongside Traditional Drugs at Genentech

Mikael Eliasson, Global Head of Innovation, Neuroscience Product Development, Genentech

3:05pm
Afternoon Refreshments and Networking
3:45pm
Fireside Chat: The First Large-Scale Acquisition of Digital Therapeutics

Chris Hogg, Chief Commercial Officer, Propeller Health
Ricardo Dos Santos, Entrepeneur in Residence, ResMed

4:30pm
Panel Discussion: What's going to stop Digital Therapeutics from Breaking Big

Moderated by Ed Cox, CEO, Dthera Sciences
Pierre Leurent
, Founder and CEO, Voluntis
Kal Patel, Co-Founder & CEO, Bright Insight, a Flex Company
Eddie Martucci, Founder & CEO, Akili Interactive
Megan Coder, Executive Director, Digital Therapeutics Alliance

5:20pm
Chair's Closing Remarks

Adam Kaufman, President & CEO, Canary Health

5:30pm
Drinks Reception
6:30pm
Close of DTx West Day 1
Download Agenda
Day 2: Wednesday, 19th February
8:00am
Day Two - Breakfast & Networking
9:00am
Chair’s Opening Remarks

Antoun Nabhan, VP, Corporate Development, Pear Therapeutics

9:10am
Fireside Chat: The First Large-Scale Acquisition of Digital Therapeutics

Chris Hogg, Chief Commercial Officer, Propeller Health
Ricardo Dos Santos, Entrepeneur in Residence, ResMed

Scaling Digital Therapeutics for World Domination
9:50am
Panel Discussion: Scaling Digital Therapeutics for Sustainable Success

Elli Kaplan, Co-Founder & CEO, Neurotrack
Chris Hogg, CCO, Propeller Health
Anand Iyer, Chief Strategy Officer, Welldoc

10:30am
Morning Refreshments and Networking
11:10am
Panel Discussion: What do Investors Really Think of Digital Therapeutics

Liz Rockett, Director, Kaiser Permanente Ventures
Vas Bailey, Partner, Artis Ventures
David Stevenson, Managing Director, Merck Global Health Innovation Fund

11:50am
Presentation: Prescription Digital Therapeutics for Neuro-Muscular Conditions

Siva Nadarajah, Co-Founder & President, JOGO Health

12:15pm
Presentation: Creating synergy with DTx: How DTx benefits healthcare system stakeholders

Kenichiro Nishii, Lead, Regulatory Affairs and Business Development, CureApp

12:40pm
Presentation: In-House production of Traditional and Digital Therapeutics for a Combination Approach

Hakim Yadi, Co-Founder & CEO, Closed Loop Medicine

1:05pm
Lunch and Networking
1:45pm
Panel Discussion: Digital Therapeutics - Lessons Learned from the Front Line

Trina Histon, Senior Principal Consultant, Prevention, Wellness and Digital Health, Kaiser Permanente
Ben Rosner, Assistant Producer, UCSF
Kara Tibbe, Training & Development Specialist, Spectrum Health
Pablo Panteoloni, VP & General Manager of Health, Headspace

2:25pm
Chairs Closing Remarks

Antoun Nabhan, VP, Corporate Development, Pear Therapeutics

2:35pm
Close of DTx West 2019
Download Agenda

Partner with us

PARTNERSHIPS
The DTx summits are the premier events for senior executives from DTx companies, Pharma, Investors, HCPs and Payers.

DTx West 2020 is the seventh summit in the DTx series.  We are expecting 300 people at the summit in San Mateo, which is what our attendees and partners tell us is the optimum size

We believe that getting the right mix of partners is critical for a successful summit for you and our attendees. The DTx summit provides a rare opportunity to showcase your business to a world-class audience.

You will be impressed with our service and truthfulness. We will be honest with you throughout the process from deciding which option is right for you to delivery on-site.

Get in touch today to learn more and avoid missing out!

Contact Us +
Partner with us

Register for the Event

Early Booking Price expires November 22nd.

For pricing and booking options please click the button to go to the registration page.

Registration